

**PATHOGENESIS OF AORTIC  
STENOSIS: IMPLICATIONS  
REGARDING IMPAIRMENT OF  
NITRIC OXIDE SIGNALLING**

**Aaron Leonid Sverdlov**  
MBBS, FRACP, FCSANZ

Department of Medicine, Faculty of Health Sciences

University of Adelaide

&

Department of Cardiology, The Queen Elizabeth Hospital

South Australia, Australia

April 2012

A thesis submitted to the University of Adelaide as the requirement  
for the degree of Doctor of Philosophy

Dedicated to my beautiful  
wife Doan and son Joshua

# TABLE OF CONTENTS

<b>TABLE OF CONTENTS</b> .....	<b>III</b>
<b>ABSTRACT</b> .....	<b>VI</b>
<b>DECLARATION</b> .....	<b>VIII</b>
<b>PUBLISHED WORKS IN WHOLE OR IN PART CONTAINED WITHIN THIS THESIS</b> .....	<b>IX</b>
<b>SCHOLARSHIPS, AWARDS AND GRANTS HELD CURRENTLY</b> .....	<b>X</b>
<b>SCHOLARSHIPS, AWARDS AND GRANTS RELATED TO THIS THESIS</b> .....	<b>XI</b>
<b>ACKNOWLEDGEMENTS</b> .....	<b>XII</b>
<b>PERSONAL BIBLIOGRAPHY</b> .....	<b>XIV</b>
PEER-REVIEWED FULL TEXT PUBLICATIONS ARISING FROM AND/OR RELATED TO THE WORK CONDUCTED TOWARDS THIS THESIS - PUBLISHED/IN PRESS .....	XIV
PEER-REVIEWED FULL TEXT PUBLICATIONS ARISING FROM AND/OR RELATED TO THE WORK CONDUCTED TOWARDS THIS THESIS - IN SUBMISSION. ....	XVI
PUBLICATIONS/PRESENTATIONS IN ABSTRACT FORM RELATED TO THIS THESIS .....	XVI
<b>LIST OF ABBREVIATIONS</b> .....	<b>XX</b>
<b>CHAPTER 1</b> .....	<b>1</b>
1.1 AGING OF THE CARDIOVASCULAR SYSTEM: AN EMERGING EPIDEMIC .....	2
1.2 CLINICAL CONSIDERATIONS .....	4
1.2.1 <i>Spectrum of aortic valve disease</i> .....	4
1.2.2 <i>Epidemiology of AS and ASc</i> .....	5
1.2.3 <i>Genetics of AS/ASc</i> .....	5
1.2.4 <i>Anatomy and histology of the aortic valve in health and disease</i> .....	8
1.2.5 <i>Detection, Experimental and Clinical Assessment of Aortic valve disease</i> .....	10
1.2.5.1 Aortic stenosis.....	10
1.2.5.1.1 Physical examination .....	10
1.2.5.1.2 Electrocardiogram.....	10
1.2.5.1.3 Catheterization .....	11
1.2.5.1.4 Echocardiography .....	11
1.2.5.1.5 Computed tomography.....	12
1.2.5.1.6 Magnetic resonance imaging (MRI) .....	13
1.2.5.2 Aortic sclerosis.....	14
1.2.5.2.1 Clinical.....	14
1.2.5.2.2 Echocardiography: general.....	14
1.2.5.2.3 <i>Echocardiography: backscatter</i> .....	15
1.2.6 <i>Clinical Factors Associated with presence of AS/ASc</i> .....	16
1.2.7 <i>Left Ventricular Hypertrophy (LVH) in the context of AS/ASc</i> .....	18
1.2.8 <i>Factors associated with clinical progression of AS/ASc</i> .....	19
1.2.9 <i>Outcomes of AS</i> .....	22
1.2.10 <i>Association of ASc with coronary event risk</i> .....	24
1.2.11 <i>Current Treatments in Clinical Practice</i> .....	25
1.2.11.1 Medical therapy.....	25
1.2.11.2 Aortic valve replacement .....	26
1.2.11.3 Percutaneous aortic valvuloplasty .....	28
1.2.11.4 New technologies for AV replacement – percutaneous transcatheter aortic valve implantation (TAVI) .....	28
1.3 MECHANISTIC CONSIDERATIONS .....	30
1.3.1 <i>Aging as a risk factor: cellular and molecular biology</i> .....	30
1.3.2 <i>Aortic valve mechanics - role of valvular endothelium and valvular interstitial cells (VICs)</i> .....	32
1.3.3 <i>Histopathological features of AS</i> .....	33
1.3.3.1 Aortic valve interstitial cells (VICs).....	33
1.3.3.2 Extracellular matrix and fibrosis .....	34
1.3.3.3 Inflammation and lipid deposition.....	35
1.3.3.4 Oxidative stress .....	36
1.3.3.5 Calcification .....	36
1.3.4 <i>Possible mechanisms for adverse outcomes associated with AS/ASc</i> .....	38
1.3.4.1 Links with atherosclerosis .....	39

1.3.4.2 Platelet dysfunction .....	39
1.3.4.3 Perturbations of NO signalling cascade .....	40
1.3.4.3.1 Endothelial dysfunction in ASc/AS .....	40
1.3.4.3.2 Platelet function .....	41
1.3.4.3.3 Vascular endothelial function .....	44
1.3.4.3.4 Endothelial progenitor cells (EPC) .....	44
1.3.4.4 Left ventricular hypertrophy (LVH).....	45
1.3.5 <i>Animal models of AS</i> .....	47
1.3.6 <i>Is AS/ASc preventable?</i> .....	50
1.3.6.1 Animal studies on slowing progression of AS .....	50
1.3.6.1.1 Statins .....	50
1.3.6.1.2 ACE Inhibitors/Angiotensin receptor-1 blockers (ACEI/ARB).....	51
1.3.6.1.3 Bisphosphonates .....	52
1.3.6.1.4 Exercise training .....	52
1.4 CLINICAL STUDIES ON SLOWING OF PROGRESSION OF AS .....	54
1.4.1 <i>Retrospective</i> .....	54
1.4.1.2 Statins.....	54
1.4.1.3 ACEI/ARB therapy .....	54
1.4.1.4 Bisphosphonates.....	55
1.4.2 <i>Prospective</i> .....	56
1.4.2.1 Lipid-lowering (predominantly statin) therapy .....	56
1.4.2.2 ACEI/ARB therapy .....	57
1.4.2.3 Aldosterone blockade.....	58
1.5 AFTER ASTRONOMER: THE CASE THAT PATHOGENESIS OF ASC/AS AND ATHEROSCLEROSIS ARE DISTINCT FROM ONE ANOTHER: EPIDEMIOLOGICAL AND BIOCHEMICAL PERSPECTIVES .....	59
1.6 SCOPE OF THIS THESIS .....	61
1.7 TABLES AND FIGURES FOR CHAPTER 1 .....	63
<b>CHAPTER 2.....</b>	<b>80</b>
2.1 INTRODUCTION .....	81
2.2 METHODS .....	86
2.2.1 <i>Study subjects</i> .....	86
2.2.2 <i>Investigations</i> .....	87
2.2.2.1 Doppler echocardiography .....	87
2.2.2.2 Ultrasound backscatter data analysis.....	87
2.2.2.3 Biochemical and physiological parameters .....	88
2.2.2.4 Statistical analyses .....	90
2.3 RESULTS .....	92
2.3.1 <i>Baseline evaluation</i> .....	92
2.3.1.1 Subject characteristics .....	92
2.3.1.2 Biochemical data .....	93
2.3.1.3 Endothelial function and platelet responsiveness to NO .....	93
2.3.1.4 Univariate correlations with AVBS scores.....	93
2.3.1.5 Stepwise multiple linear regression analyses .....	95
2.3.1.6 Binary logistic backward regression analyses .....	95
2.3.2 <i>End-of-study evaluation: data based on 204 subjects who completed follow-up</i> .....	96
2.3.2.1 Subject characteristics .....	96
2.3.2.2 Changes in AVBS .....	97
2.3.2.3 Progression of AVBS within the entire cohort .....	97
2.3.2.3.1 AVBS change as a continuous variable .....	97
2.3.2.3.2 AVBS increase as a dichotomous variable.....	98
2.3.2.3.3.1 Progression of AVBS in subjects without ASc at baseline .....	98
2.4 DISCUSSION .....	100
2.4.1 <i>Conclusions</i> .....	108
2.5 TABLES AND FIGURES FOR CHAPTER 2 .....	110
<b>CHAPTER 3.....</b>	<b>134</b>
3.1 INTRODUCTION .....	135
3.2 METHODS .....	140
3.2.1 <i>Echocardiographic diagnosis of Aortic Sclerosis (for evaluation of objective 1)</i> .....	140
3.2.2 <i>MRI measurement of LV volumes</i> .....	141
3.2.3 <i>Endothelial function</i> .....	142
3.2.4 <i>Statistics</i> .....	143
3.2.4.1 Objective 1 .....	144
3.2.4.2 Objective 2 .....	144
3.3 RESULTS .....	146

3.3.1 Objective 1.....	146
3.3.1.1 Subject Characteristics .....	146
3.3.1.2 Comparison of normal aortic valve and aortic sclerosis groups .....	146
3.3.1.3 Relationship between aortic sclerosis, LVMI and afterload .....	147
3.3.1.4 Endothelial function .....	147
3.3.1.5 Determinants of LVMI.....	147
3.3.2 Objective 2.....	148
3.3.2.1 Subject characteristics .....	148
3.3.2.2 Univariate analyses .....	148
3.4 DISCUSSION .....	150
3.4.1 Limitations.....	156
3.4.2 Conclusions.....	158
3.5 TABLES AND FIGURES FOR CHAPTER 3 .....	159
<b>CHAPTER 4.....</b>	<b>178</b>
4.1 INTRODUCTION .....	179
4.2 METHODS.....	182
4.2.1 Patient selection .....	182
4.2.2 Patient data .....	182
4.2.3 Biochemical and physiological parameters .....	183
4.2.4 Statistical analyses.....	184
4.3 RESULTS .....	186
4.3.1 Patient characteristics.....	186
4.3.2 Change in parameters of NO system with time .....	186
4.3.2.1 Platelet data .....	186
4.3.2.2 ADMA .....	187
4.3.2.3 Arterial stiffness (AIx) .....	187
4.3.2.4 EPCs.....	187
4.3.3 Univariate analyses.....	187
4.3.3.1 Correlates of baseline data .....	187
4.3.3.2 Correlates of changes in parameters over time .....	188
4.3.4 Multivariate analyses .....	190
4.3.4.1 Baseline.....	190
4.3.4.2 Changes over time.....	190
4.3.4.3 Correlations of EPC counts at the end of study .....	191
4.4 DISCUSSION .....	192
4.5 TABLES AND FIGURES FOR CHAPTER 4 .....	198
<b>CHAPTER 5.....</b>	<b>211</b>
<b>BIBLIOGRAPHY.....</b>	<b>218</b>
<b>APPENDIX: PUBLISHED WORKS IN WHOLE OR IN PART CONTAINED WITHIN THIS THESIS.....</b>	<b>250</b>

## Abstract

Aortic valve stenosis (AS) is now the most common valve disease in Western world and its prevalence and incidence are rising. The earliest clinically detectable stage of this process, aortic valve sclerosis (ASc), reflects abnormal aortic valve morphology in the absence of haemodynamic obstruction, but may progress to AS. The prevalence of ASc is as high as 25% in populations over 65 years of age: - thus it carries important epidemiological, clinical and pathophysiological implications. Despite the increased interest into studies of ASc/AS, the pathogenesis of this condition remains largely elusive, except to say that rather than the notion of being just a “wear and tear” inevitable process, it is now accepted to be an active pathophysiological process. The relevant literature is reviewed in Chapter 1.

Studies described in this thesis address the determinants of occurrence and progression of ASc in a cohort of aging subjects followed for 4 years. Novel methodology of aortic valve ultrasonic backscatter was utilized to quantitate ASc severity and progression. In the subsequent studies the effects of ASc on left ventricular hypertrophy (LVH) were evaluated in a separate cohort of healthy aging individuals, with no significant cardiovascular risk factors or hypertensive therapy. Finally, effects of aging on integrity of the nitric oxide (NO) signalling cascade were examined in the population cohort recruited for evaluation of progression of ASc.

The key findings from this thesis are:

- (1) Platelet NO responsiveness is a determinant of both the occurrence and progression of ASc, while age and BMI are determinant of occurrence only. Calcium levels and arterial stiffness correlate only with progression. Categorical assessment of progression reveals that use of inhibitors of the renin-angiotensin system is associated with lack of ASc progression.

- (2) Whilst ASc is not correlated with the development of LVH in the absence of treated hypertension, markers of NO generation and of the NO/ cyclic GMP signalling cascade in the peripheral circulation predict both LV mass index and LV diastolic function in a normal, untreated, aging population, irrespective of ASc status.
- (3) Aging is associated with both increases in ADP-induced platelet aggregation and plasma asymmetric dimethylarginine (ADMA) concentrations, and with reductions in platelet NO responsiveness. Female gender is associated with more severely impaired platelet NO responsiveness, greater arterial stiffness and a more pronounced fall in platelet NO responsiveness with time, which in turn was also observed in subjects with lower plasma vitamin D concentrations. There is a significant relationship between deterioration in platelet NO responsiveness and increases in ADMA concentrations. Finally, use of angiotensin convertin enzyme inhibitors/angiotensin receptor blockers is associated with preserved platelet NO responsiveness and lower arterial stiffness.

In summary, the aging process is associated with a remarkable degree of attenuation of NO generation and signalling, which constitutes both a correlate of ASc development/progression and of the development of LVH (although the latter is not closely associated with ASc in "normal" populations). Furthermore, the rate of deterioration of NO signalling is greatest in females, in the presence of low vitamin D levels and correlates with rises in ADMA concentrations.

## **Declaration**

I, Aaron Leonid Sverdlov, certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below\*) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

**Aaron Leonid Sverdlov**

**April 2012**



## **Published works in whole or in part contained within this thesis**

1. **Sverdlov AL**, Ngo DT, Horowitz JD. Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation. *Am J Cardiovasc Dis* 2012; 2(1):43-9.
2. **Sverdlov AL**, Ngo DT, Horowitz JD. Redefining the natural history of calcific aortic stenosis: lessons from Laennec. *J Intern Med* 2012. In press. Doi: 10.1111/j.1365-2796.2012.02520.x.
3. Nightingale AK, **Sverdlov AL**, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD. Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects. *Int J Cardiol* 2011; 150:33-8. Epub Mar 16, 2010.
4. **Sverdlov AL**, Ngo DT, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. *Nitric Oxide* 2011; 25(1): 41-46.
5. **Sverdlov AL**, Ngo DT, Chapman MJ, Akbar Ali O, Chirkov YY, Horowitz JD. The pathogenesis of aortic stenosis: not just a matter of wear and tear. *Am J Cardiovasc Dis* 2011; 1(2):185-199.
6. Ngo DTM, **Sverdlov AL**, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Determinants of occurrence of aortic sclerosis in an aging population. *J Am Coll Cardiol Img* 2009; 2:919-927.

## **Scholarships, Awards and Grants held currently**

**National Health and Medical Research Council of Australia Early Career Fellowship**

**- CJ Martin Overseas Biomedical Fellowship.** Awarded 2011. To commence 2012.

**Royal Australasian College of Physicians Margorie Hooper Scholarship.** Awarded

2010. To commence 2012.

## **Scholarships, Awards and Grants related to this thesis**

1. **Heart Foundation SA "E O Myers Trust Fund" Grant** awarded in 2009.
2. **Cardiac Society of Australia and New Zealand (CSANZ) Traveling Fellowship: AHA 2009.**
3. **CardioVascular Lipid Research Grant**, awarded for year 2008.
4. **Heart Foundation SA "J" Fund Grant**, awarded for year 2008.
5. **Faculty of Health Sciences Divisional Scholarship, University of Adelaide.**  
Awarded in 2005 (intermitted for 2006-7, and recommenced in 2008-10).

## **Acknowledgements**

First and foremost I would like to thank my main supervisor Prof John Horowitz. His guidance, encouragement and patience throughout my PhD have been more than I could hope for. He has been more than my supervisor, but my mentor both in work and in life. His enthusiasm for research and ability as a clinician-scientist are remarkable. I feel very privileged to have received such world-class training with him.

I would also like to thank Dr Yuliy Chirkov, my co-supervisor for his expert advice and his help in teaching me platelet aggregometry. Your precise ways and intellectual advice were most welcome. A/Prof Jennifer Kennedy, my other supervisor, provided a laboratory environment rich in translational research experience in aortic valve disease and for that I am grateful.

To my friend and colleague who is “suffering” through her own PhD and still found time to help me with mine: Dr Alicia Chan – thank you for all your help with EPC assay and some other laboratory experiments. Most importantly, thank you for our “soul soothing” chats to vent mutual frustrations! To my other friends and colleagues: Drs Angus Nightingale, Sharmalar Rajendran and Devan Mahadavan and– thank you for your support.

I am grateful to the echocardiography staff at the Queen Elizabeth Hospital for their help in performing detailed echocardiograms to my peculiar specifications at inconvenient hours. In particular my thanks go to Mr Ronald Wuttke, Ms Gina Velissaris and Mr Matthew Chapman.

I would like to thank Dr Ha Nguyen for help with the EPC assays, Ms Irene Stafford and Ms Tamila Heresztyn for running some of the ADMA samples. Furthermore, I would like to acknowledge help from Ms Sue Leslie and Nadine Smith, research nurses in helping me recall some of the subjects for follow up. I would also like to thank the staff of North Western Adelaide Health Study for their help with the initial recruitment of study subjects.

I would like to thank my parents, Irina and Leonid, for the way they brought me up and encouraged me to achieve my best; for their determination to bring the family to Australia so that their children can achieve their full potential in a country where ethnicity would not preclude one from achieving their best. My thanks also go to my grandparents Anna and Ilya for their encouragement, support and instilling me with strong family values. I would also like to thank my parents-in-law, Mai and Duc, for their support and help looking after my son during this journey!

Last, but most importantly, I would like to pay tribute to my wife Doan and son Joshua. Doan, your support, encouragement and advice have been tremendous and valuable especially as you have travelled this road before, getting your PhD 4 years ago. Doan has also paved the way for my research, having been the one who has done most of the work related to the initial evaluation of the patient cohort and helped with the follow-up studies. Your love and understanding have been my source of constant support. I am very lucky to have you by my side. I am particularly proud to have become a father during this journey: Joshua is truly the best thing that has happened to me and the source of endless happiness. This thesis is dedicated to you!

## Personal Bibliography

### Peer-reviewed full text publications arising from and/or related to the work conducted towards this thesis - published/in press

1. **Sverdlov AL**, Ngo DT, Horowitz JD. Redefining the natural history of calcific aortic stenosis: lessons from Laennec. *J Intern Med* 2012. In press. Doi: 10.1111/j.1365-2796.2012.02520.x.
2. Ngo DT\*, **Sverdlov AL\***, Horowitz JD. Prevention of aortic valve stenosis: a realistic therapeutic target? *Pharmacol Ther* 2012. In press. Doi: 10.1016/j.pharmthera.2012.04.001
3. **Sverdlov AL**, Ngo DT, Horowitz JD. Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation. *Am J Cardiovasc Dis* 2012; 2(1):43-9.
4. **Sverdlov AL**, Ngo DT, Chapman MJ, Akbar Ali O, Chirkov YY, Horowitz JD. The pathogenesis of aortic stenosis: not just a matter of wear and tear. *Am J Cardiovasc Dis* 2011; 1(2):185-199.
5. **Sverdlov AL**, Ngo DT, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. *Nitric Oxide* 2011; 25(1): 41-46.

6. Ngo DTM, Stafford I, **Sverdlov AL**, Qi W, Wuttke RD, Zhang Y, Kelly DJ, Weedon H, Smith MD, Kennedy JA, Horowitz JD. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. *Br J Pharmacol* 2011; 162 (3): 722-32.
7. Nightingale AK, **Sverdlov AL**, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD. Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects. *Int J Cardiol* 2011; 150:33-8. Epub Mar 16, 2010.
8. Ngo DTM, **Sverdlov AL**, McNeil JJ, Horowitz JD. Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine. *Pharmacol Res* 2009; 60(6):503-7
9. Ngo DTM, **Sverdlov AL**, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Determinants of occurrence of aortic sclerosis in an aging population. *J Am Coll Cardiol Img* 2009; 2:919-927. 5
10. **Sverdlov AL**, Taylor K, Elkington AG, Zeitz CJ, Beltrame JF. Cardiac MRI identifies the elusive perivalvular abscess. *Circulation* 2008; 118:e1-e3.
11. Ngo DTM, Stafford I, Kelly DJ, **Sverdlov AL**, Wuttke RD, Weedon H, Nightingale AK, Rosenkranz AC, Smith MD, Chirkov YY, Kennedy JA, Horowitz JD. Vitamin D<sub>2</sub> supplementation induces development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. *Eur J Pharmacol* 2008; 590:290-6.

**Peer-reviewed full text publications arising from and/or related to the work  
conducted towards this thesis - in submission.**

1. **Sverdlov AL\***, Ngo DT\*, Chan, WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD. Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. *Eur Heart J* - under review.

\* designates joint first authors

**Publications/presentations in abstract form related to this thesis**

1. **Sverdlov AL**, Ngo DTM, Chan WP, Chapman MJ, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD. Progression of Early Aortic Valve Disease: Are ACE Inhibitors Protective? Presented at AHA Scientific Sessions 2011, Orlando, USA.

*Circulation 2011; 124 (21 Suppl): A12974*

2. **Sverdlov AL**, Ngo DTM, Chirkov YY, Horowitz JD. Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D. Presented at European Society of Cardiology Congress 2011, Paris, France.

*Eur Heart J 2011; 32 (Suppl 1): 774.*

3. **Sverdlov AL**, Ngo DTM, Chirkov YY, Horowitz JD. *Insight into retardation of aortic stenosis: a therapeutic role for ACE inhibitors?* Presented at CSANZ 2011, Perth, Australia.

*Heart Lung Circ 2011; 20 (suppl 2): S208.*



4. Ngo DT, **Sverdlov AL**, Stafford I, Kelly DJ, Kennedy JA, Horowitz JD. Development of aortic valve stenosis in response to Vitamin D treatment in rabbits: role of asymmetric dimethylarginine (ADMA). Presented at the 5th International Symposium on ADMA 2010, Chicago, USA
  
5. **Sverdlov AL**, Ngo DT, Nightingale AK, Rajendran S, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. *Relationship between LV mass and diastolic function is independent of NO generation*. Presented at European Society of Cardiology Congress 2010, Stockholm, Sweden.  
  
*Eur Heart J 2010; 31 (suppl 1): 121*
  
6. **Sverdlov AL**, Ngo DT, Chan WP, Chirkov YY, Horowitz JD. *Relationship Between Endothelium-dependent and Independent Vasomotor and Platelet Dysfunction*. Oral presentation at CSANZ 2010, Adelaide, Australia.  
  
*Heart Lung Circ 2010; 19 (suppl 2): S16*
  
7. **Sverdlov AL**, Ngo DT, Nightingale AK, Rajendran S, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. *Relationship Between LV Mass and Diastolic Function is Independent of NO Generation*. Presented at CSANZ 2010, Adelaide, Australia.  
  
*Heart Lung Circ 2010; 19 (suppl 2): S52*
  
8. **Sverdlov AL**, Ngo DT, Nightingale AK, Rajendran S, Heresztyn T, Horowitz JD. *Plasma concentrations of asymmetric dimethylarginine (ADMA) predict LV mass independent of afterload*. Oral presentation at the American Heart Association Scientific Sessions 2009, Orlando, USA.

9. **Sverdlov AL**, Ngo DT, McNeil JJ, Horowitz JD. *Diabetes is associated with paradoxically low plasma concentrations of asymmetric dimethylarginine (ADMA)*. Presented at the 4<sup>th</sup> International Symposium on ADMA 2008, Bregenz, Austria.

10. **Sverdlov AL**, Ngo DT, McNeil JJ, Horowitz JD. *Diabetes is associated with paradoxically low plasma concentrations of asymmetric dimethylarginine (ADMA)*. Presented at CSANZ 2008, Adelaide, Australia.

*Heart Lung Circ 2008; 17 (suppl 3): S134*

11. **Sverdlov AL**, Ngo DT, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Predictors of elevated augmentation index in an ageing population: beyond hypertension. Presented at CSANZ 2007, Christchurch, New Zealand.

*Heart Lung Circ 2007; 16 (suppl 2): S69-70*

12. Ngo DT, **Sverdlov AL**, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Aortic valve sclerosis is associated with impairment of platelet responsiveness to nitric oxide. Presented at CSANZ 2007, Christchurch, New Zealand.

*Heart Lung Circ 2007; 16 (suppl 2): S69*

13. Nightingale AK, Rajendran S, **Sverdlov A**, Mishra K, Ngo D, Heresztyn T, Horowitz JD. *Aortic sclerosis precedes development of systemic endothelial dysfunction*. Presented at European Society of Cardiology/World Congress of Cardiology 2006, Barcelona, Spain.

*Eur Heart J 2006; 27 (suppl 1): 743*

14. Ngo DT, **Sverdlov AL**, Willoughby SR, Nightingale AK, Chirkov YY, Horowitz JD.  
*Correlates of aortic sclerosis: a population study*. Presented at CSANZ 2006,  
Canberra, Australia.

*Heart Lung Circ 2006; 15 (suppl 1): S77*

15. Nightingale AK, Rajendran S, Mishra K, **Sverdlov A**, Ngo DT, Horowitz JD.  
*Vascular responses to GTN but not salbutamol decline with age*. Presented at  
EUROECHO 9 – 2005, Florence, Italy.

*Eur J Echocardiogr 2005; 6 (suppl 1): S86*

## List of abbreviations

5-HT	Serotonin
ACE	Angiotensin converting enzyme
ACEI	ACE inhibitor
ADMA	Asymmetric dimethylarginine
ADP	Adenosine diphosphate
ANCOVA	Analysis of co-variance
Ang II	Angiotensin II
apo	Apolipoproteins
ARB	Angiotensin receptor blockers
AS	Aortic stenosis
ASc	Aortic sclerosis
AVA	Aortic valve area
AVBS	Aortic valve ultrasonic backscatter score
AVp	Aortic valve pressure gradient (transvalvular pressure gradient)
AVR	Aortic valve replacement
AVv	Aortic valve velocity (transvalvular velocity)
BAV	Bicuspid aortic valve
BMI	Body mass index
BMP	Bone morphogenic protein
BNP	Brain natriuretic peptide
BSA	Body surface area
CAD	Coronary artery disease
CFR	Coronary flow reserve
CMs	Cardiomyocytes

CrCl	Cretinine clearance
CRP	C-reactive protein
CT	Computed tomography
CTx	C-terminal telopeptide of collagen type 1
DDAH	Dimethylarginine dimethylaminohydrolase
DNA	Deoxyribonucleic Acid
EF	Ejection fraction
eNOS	Endothelial nitric oxide synthase
EPC	Endothelial progenitor cells
FMD	Flow mediated dilatation
GMP	Guanosine monophosphate
GP	Glycoprotein
GTN	Glyceryl trinitrate
HF/HC	High fat/high carbohydrate
hs-CRP	High sensitivity CRP
HT	Hypertension
IL	Interleukin
INOS	Inducible nitric oxide synthase
LDL	Low density lipoprotein
LDLr -/-	LDL receptor deficient
L-NAME	L-Nitro-Arginine Methyl Ester
LV	Left ventricle
LVH	Left ventricular hypertrophy
MC	Mast cell
MGP	Matrix Gla-protein

MMP	Matrix metalloproteinases
MRI	Magnetic resonance imaging
NAD(P)H	Nicotinamide Adenine Dinucleotide (Phosphate) Hydrogen
nNOS	Neuronal nitric oxide synthase
NO	Nitric oxide
NOS	Nitric oxide synthase
PINP	N-terminal peptide of procollagen I
PAI-I	Plasminogen activator inhibitor-1
PRMT	Protein arginine methyltransferase
RAAS	Renin-angiotensin-aldosterone system
RANK	Receptor Activator of Nuclear Factor $\kappa$ B
RANKL	Receptor Activator of Nuclear Factor $\kappa$ B ligand
ROS	Reactive oxygen species
sGC	Soluble guanylate cyclase
SNP	Sodium nitroprusside
TAVI	Percutaneous transcatheter aortic valve implantation
TGF- $\beta$	Transforming growth factor beta
TNF- $\alpha$	Tumor necrosis factor-alpha
TXNIP	Thioredoxin-interacting protein
VICs	Valvular interstitial cells
vWf	von Willebrand factor